Licensing · Latin America · Announced 22 May 2026

Polpharma Biologics → Tuteur

Polpharma Biologics granted Argentina's Tuteur exclusive Latin American rights, excluding Brazil, to commercialise an unnamed biosimilar for autoimmune disease, with regulatory submission expected within three years.

Parties: Polpharma Biologics (Switzerland) → Tuteur (Argentina)

Deal type
Licensing
Value
Undisclosed
Territory
Latin America excluding Brazil
Asset
Biosimilar candidate (not named)
Announced
22 May 2026

Our analysis

Why this matters

Polpharma Biologics and Tuteur signed an exclusive licensing agreement, reported on 22 May 2026, to commercialise a biosimilar for an autoimmune disease across Latin America, excluding Brazil. The molecule was not named. Regulatory submission is anticipated within the next three years. Financial terms were not disclosed.

The deal fills in Polpharma's regional map: it licensed Brazil to Libbs Farmacêutica in December 2025 and signed MS Pharma for MENA (guselkumab, ocrelizumab and vedolizumab biosimilars) in September 2025.

The full analysis is free to read with a work email on this page.

Source: Pearce IP

Latest deals

All Latin America deals → · All licensing deals → · Browse all emerging-market pharma deals →